Here are the 10-K annual reports from Exicure, Inc. (XCUR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow XCUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XCUR filings page.
Exicure, Inc. reports that it has halted its historical biotech R&D, sold essentially all prior intellectual property, and is now focused on exploring strategic alternatives, including acquisitions and partnerships, potentially outside biotechnology and with an emphasis on Asia.
At December 31, 2025, cash and cash equivalents were about $3.7 million, with a 2025 net loss of $4.9 million and an accumulated deficit of $223.0 million, leading to “substantial doubt” about its ability to continue as a going concern without near‑term financing.
The company acquired GPCR Therapeutics USA Inc. in January 2025; GPCR USA completed a Phase 2 trial in January 2026, and Exicure plans a $1.0 million milestone payment in stock in 2026. HiTron owns about 25% of common stock, increasing governance influence concerns. Risks include Nasdaq delisting, significant legal proceedings and settlements, difficulties redeeming $2.090 million of convertible notes, unpaid rent disputes of about $0.7 million, and limited internal controls and cybersecurity resources.